Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development	$ 3,939	$ 5,602
General and administrative	5,158	5,895
Total operating expenses	9,097	11,497
Operating loss	(9,097)	(11,497)
Other income / (expense):
Interest income / (expense), net	19	254
Warrant modification expense		(666)
Other income	4	79
Other income / (expense), net	23	(333)
Net loss	$ (9,074)	$ (11,830)
Net loss per share, basic and diluted	$ (1.31)	$ (35.28)
Weighted average number of common shares outstanding, basic and diluted (In Shares)	6,902,693	335,350